ClinicalTrials.gg
RecruitingNCT07738406Updated Jul 31, 2026

Robot-Assisted Closed Reduction and Internal Fixation for Distal Femoral Fractures

An interventional study of Robot-assisted closed reduction and Conventional fracture reduction and internal fixation in Supracondylar Femoral Fractures and Femoral Fractures, sponsored by Beijing Jishuitan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Beijing Jishuitan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to evaluate the clinical efficacy and safety of an intelligent robotic system for the closed reduction of extra-articular supracondylar femoral fractures (Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association AO/OTA 33-A). Traditional manual reduction for supracondylar femoral fractures is often challenging due to strong muscle pull, heavily relying on the surgeon's experience and frequently requiring repeated fluoroscopy. This clinical trial compares robot-assisted closed reduction against traditional surgeon-led reduction methods. The primary goal is to determine if the robotic system improves the precision of bone alignment (excellent and good reduction rate) and functional recovery while reducing surgical radiation exposure.

02

Conditions studied

  • Supracondylar Femoral Fractures
  • Femoral Fractures

Browse trials for

Keywords

  • Fracture Fixation
  • Robotic Surgical Procedures
  • Minimally Invasive Surgical Procedures
  • Anatomic Reduction Standard
  • Artificial Intelligence
03

In context

Femoral Fractures

186 studies on the registry are indexed under Femoral Fractures; 38 are open to participants now.

This study's planned enrollment of 80 is above the median of 61 across 114 interventional studies indexed under Femoral Fractures.

Browse Femoral Fractures studies →

Lead sponsor

Beijing Jishuitan Hospital is the lead sponsor of 44 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years old
  • Unilateral, acute, closed extra-articular supracondylar femoral fracture (Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association AO/OTA 33-A)
  • Time from injury to surgery ≤21 days
  • Able to walk independently before injury (assistive devices allowed)

Exclusion criteria

Exclusion Criteria:

  • Open fractures or multiple severe traumas requiring priority treatment
  • Asymmetrical lower extremities, or prior malunion of the ipsilateral femur, or pre-existing deformities significantly affecting rotation/length evaluation
  • Unilateral fractures combined with other sites
  • Pathological fractures (tumor or metabolic)
  • Prior complex implants in place or previous surgeries significantly affecting evaluation
  • Active infection or severe systemic medical (unable to tolerate anesthesia/surgery)
  • Cognitive impairment, poor compliance, pregnancy, or lactation
  • Deemed unsuitable by the investigator (e.g., unable to follow up, or extreme obesity severely limiting the surgical or robotic workspace)
  • Refused randomization or enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Robot-Assisted Group

    Automated/human-robot collaborative closed fracture reduction powered by an intelligent robotic system, followed by distal femoral locking plate fixation via MIPO technique

    Device: Robot-assisted closed reduction

  • Active comparator
    Traditional Group

    Conventional closed or open fracture reduction performed entirely by the surgical team under ordinary C-arm fluoroscopy, followed by standard fixation (plates or intramedullary nails)

    Device: Conventional fracture reduction and internal fixation

Interventions

  • DeviceRobot-assisted closed reduction

    The patient undergoes automated or human-robot collaborative closed fracture reduction powered by an intelligent robotic system. The system integrates deep-learning-based bone segmentation, automatic reduction planning, and a self-adaptive 2D-3D image registration framework to achieve sub-millimeter positioning feedback and force-position collaborative security gates. Following successful reduction, internal fixation is performed using a distal femoral locking compression plate (LCP-DF) via the minimally invasive percutaneous plate osteosynthesis (MIPO) technique.

  • DeviceConventional fracture reduction and internal fixation

    The patient undergoes conventional closed or open fracture reduction performed entirely by the surgical team based on traditional clinical experience under ordinary C-arm fluoroscopic guidance. Internal fixation is achieved using standard distal femoral locking plates or intramedullary nails (with dual-plate fixation permitted when indicated for medial bone defects or collapse) according to the surgeon's choice and standard of care.

06

What researchers measure

Primary outcomes

  1. Rate of Excellent or Good Closed Fracture Reduction Assessed by Postoperative Low-Dose CT-Based 3D Quantitative Reduction Grading Criteria

    The percentage of patients achieving "Excellent" or "Good" anatomical closed reduction. Reduction quality is measured on post-op CT via RadiAnt DICOM Viewer and 3D Slicer based on the worst-performing of 3 dimensions: 1. Separation/shortening displacement: Excellent (≤3mm), Good (\>3-5mm), Fair (\>5-10mm), Poor (\>10mm). 2. Angulation deformity: Excellent (≤3°), Good (\>3-5°), Fair (\>5-10°), Poor (\>10°). 3. Rotational deformity: Excellent (≤3°), Good (\>3-5°), Fair (\>5-10°), Poor (\>10°). The final reduction grade is determined by the lowest category among these parameters, and the primary outcome represents the proportion of patients graded as Excellent or Good.

    Time frame: From completion of surgery to postoperative low-dose CT assessment, assessed up to 2 weeks after surgery

Secondary outcomes

  1. Total Operation Time Measured in Minutes

    Total operation time will be measured in minutes and defined as the duration from initial skin incision to completion of skin closure.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  2. Number of Intraoperative C-Arm Fluoroscopy Shots

    The number of intraoperative fluoroscopy shots taken using the C-arm during the surgical procedure will be recorded.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  3. Intraoperative Blood Loss Measured in Milliliters

    The estimated total volume of blood loss during the surgical procedure will be recorded in milliliters.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  4. Length of Hospital Stay Measured in Days

    The length of hospital stay will be recorded in days from admission to hospital discharge.

    Time frame: From hospital admission to hospital discharge, assessed up to 30 days

  5. Robot-Assisted Reduction Planning and Execution Time Measured in Minutes in the Experimental Group

    For participants assigned to the experimental group, the robot-assisted reduction planning and execution time will be recorded in minutes. This time is defined as the duration from completion of robotic arm setup to completion of the reduction maneuver.

    Time frame: From initial skin incision to completion of the reduction maneuver, assessed up to 8 hours

  6. Time to Radiographic Fracture Union Assessed by Standard X-Ray

    Time to radiographic fracture union will be measured in weeks using standard anteroposterior and lateral X-rays. Fracture union is defined as cortical bridging in at least 3 of 4 cortices with no significant pain during weight-bearing. Low-dose CT may be used to confirm fracture union in uncertain cases.

    Time frame: From completion of surgery to the first documented radiographic evidence of fracture union, assessed up to 6 months after surgery

  7. Radiographic Fracture Union Rate Assessed by Standard X-Ray

    The percentage of participants achieving radiographic fracture union will be assessed using standard anteroposterior and lateral X-rays. Low-dose CT may be used to confirm fracture union in uncertain cases.

    Time frame: From completion of surgery to the first documented radiographic evidence of fracture union, assessed up to 6 months after surgery

  8. American Knee Society Score

    The American Knee Society Score (AKSS) is used to evaluate the clinical outcomes and functional status of the knee joint post-operation. The total score ranges from 0 to 100, with a higher score indicating better knee function and a superior clinical outcome.

    Time frame: From baseline to 1 month, 3 months and 6 months after surgery

  9. Lower Extremity Functional Scale

    The Lower Extremity Functional Scale (LEFS) is used to evaluate the patient's ability to perform everyday tasks and lower extremity function. The score ranges from 0 to 80, with higher scores representing better functional status.

    Time frame: From baseline to 1 month, 3 months and 6 months after surgery

  10. EuroQol 5-Dimension 5-Level Health-Related Quality of Life

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire is used to assess health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level scale, and health states are converted into an index score ranging from less than 0 to 1, where higher scores mean a better quality of life.

    Time frame: From baseline to 1 month, 3 months and 6 months after surgery

  11. EuroQol Visual Analogue Scale Score

    The EuroQol Visual Analogue Scale (EQ VAS) provides a quantitative measure of the patient's self-rated overall health status. The score is recorded on a visual scale ranging from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: From baseline to 1 month, 3 months and 6 months after surgery

  12. Incidence of Intraoperative Complications

    The percentage of participants experiencing intraoperative complications, including neurovascular injury, cortical perforation, abnormal bleeding, device failure, registration failure requiring manual takeover or change of reduction strategy, will be recorded.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  13. Incidence of Postoperative Complications

    The percentage of participants experiencing postoperative complications, including wound problems or infection, thrombotic events, internal fixation failure, or loss of reduction, will be recorded.

    Time frame: From completion of surgery to postoperative complication assessment, assessed up to 6 months after surgery

  14. Incidence of Reoperation

    The percentage of participants requiring reoperation after the index surgery will be recorded.

    Time frame: From completion of surgery to reoperation assessment, assessed up to 6 months after surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07738406
Lead sponsor
Beijing Jishuitan Hospital
Collaborators
Aerospace Center Hospital
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Jul 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Chunpeng Zhao, MD / Chief Physician
Contact
zcpllza2008@163.com
+86 18610012704

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion